Welcome to our dedicated page for QIAGEN N.V. SEC filings (Ticker: QGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QIAGEN N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QIAGEN N.V.'s regulatory disclosures and financial reporting.
Form 144 filed for QIAGEN N.V. (QGEN) reports a proposed sale of 18,577 common shares with an aggregate market value of $910,286, to be sold on 08/14/2025 on the NYSE. The filing lists total outstanding shares of 216,556,000, and shows the securities were acquired as performance shares on 02/21/2023 (9,756 shares), 02/27/2025 (4,736 shares) and 02/28/2025 (4,085 shares). The form also discloses two sales on 08/13/2025 by Roland Sackers totaling 50,000 shares for combined gross proceeds of $2,456,435.00. The filer signs the standard attestation that no material nonpublic information is known.
Qiagen N.V. (QGEN) disclosure shows a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,456,435.00. With 216,556,000 shares outstanding, the proposed block represents roughly 0.023% of the company. The shares were received as performance shares on 02/21/2023 (15,378 shares) and 02/28/2023 (34,622 shares). The filing reports “Nothing to Report” for sales in the past three months and includes the seller's attestation that they are not aware of undisclosed material adverse information.
Wellington Management entities disclosed beneficial ownership of 26,023,940 shares of Qiagen N.V. (CUSIP N72482206), equal to 11.95% of the outstanding common stock. The filing shows shared voting power of 20,289,753 shares and shared dispositive power of 26,023,940 shares. The reporting persons are multiple Wellington entities, some classified as holding companies and one as an investment adviser, and the securities are owned of record by clients of Wellington investment advisers. The statement affirms the holdings are held in the ordinary course of business and not for the purpose of changing or influencing issuer control.